


# AJJ Healthcare Management secures framework agreement with NUS and NTU for the supply of Reagents

Announcement on new tender award

3 April 2024




Further to the framework agreement announced on 2nd January on the framework agreement with the National University of Singapore (“NUS”) to supply laboratory and life sciences solutions, AJJ Medtech is thrilled to announce that **AJJ Medtech’s subsidiary AJJ Healthcare has won another mid-long term tender contract for the supply of life sciences consumables and reagents to Nanyang Technological University (“NTU”) and the National University of Singapore (“NUS”) for over 150 items and with a potential contract value of S\$2.5 million.** This contract begins on 17 April spans a duration of one year, with the universities holding the option to extend annually for up to two additional years.

Reagents are essential chemical agents used in laboratories and clinical settings to detect and analyze other substances with high precision. Our product suite is enhanced through partnerships, offering an array of premium reagents that conform to stringent CE and FDA regulatory standards. These reagents are integral to academic researches with studies published within esteemed journals such as “Nature” and “Cell”.

A key aspect of our success is the meticulous attention to cold chain logistics, essential for the integrity of life sciences consumables and reagents. Our inventory management system ensures stringent temperature control between 4°C to -20 ° C with temperature-controlled cargos and storage requirements to uphold quality standards.

Dr. Tan Wei Jie, Director of Business Development, who spearheaded the project with exceptional supply chain management expertise. "Securing the framework agreement with NTU and NUS underscores AJJ Medtech's capability in delivering excellence and innovation. The prominence of our reagents, including the Mycoplasma Detection Kit, Universal Blue SYBR Green qPCR Master Mix, and Phosphatase Inhibitor, is indicative of the extensive scope and exceptional quality we provide to meet the sophisticated demands of the scientific and medical communities."

AJJ Medtech's achievement in winning this tender is not merely a business victory but a validation of our strategic approach, combining quality product offerings with unparalleled service and a competitive pricing strategy.



For more information on our reagents, please visit <https://www.ajjhealthcare.com/in-vitro-diagnostics-and-life-sciences/reagent>

For more information, please contact:

Investor Relations Office  
+65 6908 4251  
[investor@ajjmedtech.com.sg](mailto:investor@ajjmedtech.com.sg)

## About AJJ Medtech Holdings Limited

AJJ Medtech Holdings Limited (“AJJ Medtech”, the “Company,” “our,” or “we”), SGX: 584, formerly OEL (Holdings) Limited, is at the forefront in the healthcare technologies, providing integrated medtech solutions across Singapore and Southeast Asia. We deliver a comprehensive product ecosystem that improves healthcare affordability, efficiency and effectiveness along the patient care pathway, thereby improving the experience for patients and healthcare practitioners. The Company focuses on the development, manufacturing, sales and distribution of technology-driven healthcare equipment and single-use devices. In addition, we develop and integrate complementary digital, artificial intelligence, and robotics solutions, designed to optimise diagnostics and clinical support. To support the complex needs of Singapore’s and Southeast Asia’s healthcare system, we offer resilient and high-quality product turn-key supply chain solutions to overcome key challenges and setting new standards in healthcare delivery.

## Our Subsidiaries



**AJJ**  
HEALTHCARE MANAGEMENT PTE LTD

